Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 6.84%, which has investors questioning if this is right ...

Arcturus Therapeutics has a 52-week low of $8.04 and a 52-week high of $45.00. Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last released its quarterly earnings data on Thursday, March 6th.

SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Richmond American Homes of Florida, LP, a subsidiary of M.D.C. Holdings, Inc., is pleased to announce that it recently ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive is the first in the new sa-mRNA class to be approved for marketing in the EU. The importance of biosimilars only continues to grow ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive is the first in the new sa-mRNA class to be approved for marketing in the EU. The importance of biosimilars only continues to grow ...

This company does not have a dividend history.

Founded in 2004 and headquartered in Lexington, MA, Aldeyra Therapeutics is advancing a pipeline of therapies targeting immune-mediated diseases by modulating reactive aldehyde species (RASP), an ...

President Trump directs agencies to repeal regulations without notice and comment rulemaking. President Donald Trump issued a Presidential ...